Advertisement
Screener

AGIOS PHARMACEUTICALS, INC. (AGIO) Net Margin

AGIOS PHARMACEUTICALS, INC. Net Margin

Net margin is the percentage of revenue a company keeps as profit after every expense and tax. It is net income divided by revenue, and the table shows both amounts beside the percentage. A higher net margin means more of each sales dollar reaches the bottom line. One-time gains, write-downs and tax items pass through net income, so a single period's net margin can move for reasons unrelated to the underlying business. Quarterly and annual points each use the amounts filed for that same period, so a single quarter can swing with the seasons.

  • AGIOS PHARMACEUTICALS, INC. net margin for the quarter ending 2026-06-30 was -225.06%, a change of 674.34% year-over-year.
  • AGIOS PHARMACEUTICALS, INC. net margin for the quarter ending 2026-03-31 was -477.74%, a change of 545.52% year-over-year.
  • AGIOS PHARMACEUTICALS, INC. net margin for the quarter ending 2025-12-31 was -541.09%, a change of 358.47% year-over-year.
  • AGIOS PHARMACEUTICALS, INC. net margin for the quarter ending 2025-09-30 was -803.05%, a 107.59% decline year-over-year.
  • AGIOS PHARMACEUTICALS, INC. net margin for fiscal 2025 was -764.01%, a 141.39% decline from fiscal 2024.
  • AGIOS PHARMACEUTICALS, INC. net margin for fiscal 2024 was 1845.92%, a change of 3158.56% from fiscal 2023.
  • AGIOS PHARMACEUTICALS, INC. net margin for fiscal 2023 was -1312.63%, a change of 315.18% from fiscal 2022.
  • AGIOS PHARMACEUTICALS, INC. net margin for fiscal 2022 was -1627.82%.
Available history
2011-12-31 to 2026-06-30
Data captured

Historical Net Margin

DateNet MarginNet incomeRevenue
2026-06-30-225.06%-$100.7M$44.75M
2026-03-31-477.74%-$99.11M$20.75M
2025-12-31-541.09%-$108.04M$19.97M
2025-09-30-803.05%-$103.43M$12.88M
2025-06-30-899.40%-$112.02M$12.46M
2025-03-31-1023.25%-$89.29M$8.73M
2024-12-31-899.56%-$96.52M$10.73M
2024-09-3010574.69%$947.92M$8.96M
2024-06-30-1115.71%-$96.12M$8.62M
2024-03-31-995.84%-$81.55M$8.19M
2023-12-31-1350.70%-$95.94M$7.1M
2023-09-30-1234.27%-$91.32M$7.4M
2023-06-30-1248.60%-$83.81M$6.71M
2023-03-31-1444.43%-$81.02M$5.61M
2022-12-31847.47%$36.53M$4.31M
2022-09-30-2325.00%-$81.75M$3.52M
2022-06-30-1644.68%-$91.81M$5.58M
2022-03-31-11391.11%-$94.77M$832,000.00
2020-12-3161.36%-$97.66M-$159.15M
2020-09-30-285.19%-$98.98M$34.71M
2020-06-30-242.26%-$90.48M$37.35M
2020-03-31-46.22%-$40.26M$87.1M
2019-12-31-288.80%-$102.35M$35.44M
2019-09-30-407.98%-$106.17M$26.02M
2019-06-30-419.02%-$109.87M$26.22M
2019-03-31-307.93%-$93.08M$30.23M
2018-12-31-305.85%-$91.79M$30.01M
2018-09-30-622.87%-$94.66M$15.2M
2018-06-30-170.10%-$68.75M$40.41M
2018-03-31-1036.58%-$90.83M$8.76M
2017-12-31-900.96%-$88.29M$9.8M
2017-09-30-679.14%-$77.14M$11.36M
2017-06-30-732.26%-$83.08M$11.35M
2017-03-31-629.67%-$66.17M$10.51M
2016-12-31-249.41%-$56.49M$22.65M
2016-09-30-699.32%-$62.83M$8.99M
2016-06-30-801.85%-$55.95M$6.98M
2014-06-30-217.81%-$18.3M$8.4M
2014-03-31-145.81%-$12.25M$8.4M
2013-12-31-183.60%-$12.38M$6.74M
2013-09-30-178.32%-$11.18M$6.27M
2013-06-30-136.83%-$8.62M$6.3M
2013-03-31-114.73%-$7.23M$6.3M
2012-12-31-84.57%-$5.31M$6.28M
2012-09-30-74.11%-$4.65M$6.27M
2012-06-30-87.67%-$5.51M$6.29M

Annual Net Margin

DateNet MarginNet incomeRevenue
2025-12-31-764.01%-$412.78M$54.03M
2024-12-311845.92%$673.73M$36.5M
2023-12-31-1312.63%-$352.09M$26.82M
2022-12-31-1627.82%-$231.8M$14.24M
2019-12-31-348.97%-$411.47M$117.91M
2018-12-31-366.61%-$346.03M$94.39M
2017-12-31-731.60%-$314.67M$43.01M
2016-12-31-283.97%-$198.47M$69.89M
2015-12-31-199.14%-$117.73M$59.12M
2014-12-31-81.86%-$53.5M$65.36M
2013-12-31-154.25%-$39.41M$25.55M
2012-12-31-80.07%-$20.1M$25.11M
2011-12-31-108.56%-$23.71M$21.84M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Zymeworks Inc. (ZYME)United States$1.902B-12.44
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Generate Biomedicines, Inc. (GENB)United States$2.052B
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55